SEC Form 4
TScan Therapeutics, Inc. (TCRX) insider trading
In the 12 months to Oct 26, 2026, one TCRX insider reported open-market purchases of $145.5K across 1 filing; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $145.5K
- 1 filing · Weston Nichols, 10% owner
Who traded TCRX, and when
- Purchase
TCRX daily close from Oct 27, 2025 to Oct 26, 2026, between $0.18 and $2.28, last $0.18. 0 sale and 1 purchase filings by 1 insider, marked at their filing dates. Weston Nichols, 10% owner: bought $145.5K across 1 filing, first filed Dec 23, 2025, last Dec 23, 2025.
Largest mark · tap a row for others
Weston Nichols · 10% owner
Purchase $145,526
161,801 shares at $0.90 avg
Filed Dec 23, 2025 · traded Dec 19
Close on filing date $0.91
Weston Nichols · 10% owner
10% owner
$145.5K boughtOpen-market trades
1 filing in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Weston Nichols | 10% owner | — | $145.5K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Weston Nichols 10% owner | Purchase | 161,801 | $0.90 | $145.5K | 8,019,148 |
GET /stocks/filings/vX/form-4?tickers=TCRX&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"TCRX"
],
"issuer_cik": "0001783328",
"owner_cik": "0001910456",
"accession_number": "0000902664-25-005396",
"form_type": "4",
"filing_date": "2025-12-23",
"period_of_report": "2025-12-19",
"issuer_name": "TScan Therapeutics, Inc.",
"issuer_trading_symbol": "TCRX",
"owner_name": "Lynx1 Capital Management LP",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2025-12-23",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 6232,
"transaction_price_per_share": 0.8989,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 8019148,
"transaction_value": 5601.9448,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnote",
"footnotes": [
{
"id": "F3",
"description": "The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8958 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."
},
{
"id": "F2",
"description": "The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."
}
]
},
{
"tickers": [
"TCRX"
],
"issuer_cik": "0001783328",
"owner_cik": "0001746376",
"accession_number": "0000902664-25-005396",
"form_type": "4",
"filing_date": "2025-12-23",
"period_of_report": "2025-12-19",
"issuer_name": "TScan Therapeutics, Inc.",
"issuer_trading_symbol": "TCRX",
"owner_name": "Nichols Weston",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2025-12-22",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 75500,
"transaction_price_per_share": 0.9,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 8012916,
"transaction_value": 67950,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnote",
"footnotes": [
{
"id": "F2",
"description": "The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 2 records
- Grants and awards2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has TScan Therapeutics, Inc.'s CEO sold stock?
No. Gavin MacBeath (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is TCRX’s insider data?
These are TCRX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track TCRX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for TCRX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.